Phaseline

Companies › Allotera Therapeutics

Allotera Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
WU-CART-007
Anti-CD7 allogeneic CAR-T cell therapy
CD7Phase 2T-cell Acute Lymphoblastic LeukemiaDec 2026
WU-NK-101
NK cell therapy
–Phase 1Colorectal Cancer Metastatic–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05674526WU-NK-101Phase 1Colorectal Cancer MetastaticOncologySep 2025
NCT06514794WU-CART-007Phase 2T-cell Acute Lymphoblastic LeukemiaOncologyDec 2026

Targets

CD7 (1)

Companies with the same targets

PersonGen BioTherapeutics (Suzhou) Hebei Senlang Biotechnology

Companies built like this

Scancell PersonGen BioTherapeutics (Suzhou) Hebei Senlang Biotechnology Diakonos Oncology ImmVira Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.